Plain-English translation of NCT07483983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called in people who have advanced lung cancer or pancreatic cancer with a specific genetic change (KRAS G12D mutation). The medication is given as an intravenous infusion (through a vein) once a week in cycles of 21 days. Researchers will also collect blood and tumor samples to understand how the treatment works and why some patients' cancers might stop responding to it over time.
Many people with these aggressive cancers run out of treatment options after standard therapies stop working. This medication targets a specific genetic mutation that is common in these cancers, and this trial aims to see if it can help patients whose other treatments have failed.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the medication as an intravenous infusion once a week, with each treatment cycle lasting 21 days. You will need to have tumor biopsies (tissue samples) and blood draws taken before starting treatment, during treatment, and when treatment ends — especially if your cancer stops responding after initially improving. You will continue treatment until your cancer progresses, you experience unacceptable side effects, or you decide to withdraw from the study.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France